BioMotiv and BMS to Launch Anteros Pharmaceuticals

Shots:

• BioMotiv and BMS launch its first company, Anteros Pharmaceutical under a collaboration signed b/w the companies in Sept’2019
• BMS will provide the IP, data and reagents for a series of small molecules while BioMotiv, working in collaboration with Yale will be solely responsible for research and development. Following the nomination of Anteros’ preclinical candidate, BMS has the option to acquire Anteros under pre-agreed terms
• Anteros will focus on refining a new class of therapies for fibrotic and inflammatory diseases targeting unmet medical needs of millions of patients

Click here ­to­ read full press release/ article | Ref: BMS | Image: BioMotiv